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Abstract
Background: To understand the evolutionary steps required for a virus to become virulent in a new host, a
human influenza A virus (IAV), A/Hong Kong/1/68(H3N2) (HK-wt), was adapted to increased virulence in the mouse.
Among eleven mutations selected in the NS1 gene, two mutations F103L and M106I had been previously detected
in the highly virulent human H5N1 isolate, A/HK/156/97, suggesting a role for these mutations in virulence in mice
and humans.
Results: To determine the selective advantage of these mutations, reverse genetics was used to rescue viruses
containing each of the NS1 mouse adapted mutations into viruses possessing the HK-wt NS1 gene on the A/PR/8/
34 genetic backbone. Both F103L and M106I NS1 mutations significantly enhanced growth in vitro (mouse and
canine cells) and in vivo (BALB/c mouse lungs) as well as enhanced virulence in the mouse. Only the M106I NS1
mutation enhanced growth in human cells. Furthermore, these NS1 mutations enhanced early viral protein
synthesis in MDCK cells and showed an increased ability to replicate in mouse interferon b (IFN-b) pre-treated
mouse cells relative to rPR8-HK-NS-wt NS1. The double mutant, rPR8-HK-NS-F103L + M106I, demonstrated growth
attenuation late in infection due to increased IFN-b induction in mouse cells. We then generated a rPR8 virus
possessing the A/HK/156/97 NS gene that possesses 103L + 106I, and then rescued the L103F + I106M mutant.
The 103L + 106I mutations increased virulence by >10 fold in BALB/c mice. We also inserted the avian A/Ck/
Beijing/1/95 NS1 gene (the source lineage of the A/HK/156/97 NS1 gene) that possesses 103L + 106I, onto the A/
WSN/33 backbone and then generated the L103F + I106M mutant. None of the H5N1 and H9N2 NS containing
viruses resulted in increased IFN-b induction. The rWSN-A/Ck/Beijing/1/95-NS1 gene possessing 103L and 106I
demonstrated 100 fold enhanced growth and >10 fold enhanced virulence that was associated with increased
tropism for lung alveolar and bronchiolar tissues relative to the corresponding L103F and I106M mutant.
Conclusions: The F103L and M106I NS1 mutations were adaptive genetic determinants of growth and virulence in
both human and avian NS1 genes in the mouse model.
Introduction
IAV have now caused 4 pandemics in the past century,
the most lethal being the 1918 Spanish Flu pandemic,
where global mortality exceeded 20 million [1]. In addi-
tion, several new viral subtypes with presumed pan-
demic potential have arisen including virulent avian
s t r a i n so fH 7 N 7[ 2 ] ,H 9 N 2[ 3 ]a n dH 5 N 1[ 4 ]t h a th a v e
demonstrated an increased capability to infect, replicate
and cause severe disease in humans. There is thus a
need to identify genetic mutations that control host
range and virulence so that viruses with the potential to
cause virulent pandemics in humans can be identified
and monitored.
Increased virulence of avian HPAI H5 and H7 IAVs
require the presence of a multi-basic amino acid HA clea-
vage site [5], however this feature is not sufficient to con-
fer high virulence and further analysis indicates that
virulence is polygenic and requires additional mutant
genes [6]. Key mutations in the PB2 gene increased patho-
genicity and viral transmission such as E627K and D701N
[7] and mutation sites in H3 HA1 and HA2 subunits,
G218W and T156N respectively, have been shown to
affect both growth and virulence in the mouse [8]. Further
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of the HKMA variant demonstrate that all mutated gen-
ome segments enhanced disease severity including the
NS1 V23A mutation that increased virulence by 10
0.8 fold
[9]. Here, we extend the experimental mouse model to
identify two adaptive mutations in the NS1 gene, F103L
and M106I that have previously been observed in fatal
human infections with A/HK/156/97 (H5N1) [10].
NS1 is a multifunctional protein that binds both ssRNA
and dsRNA [11,12] and interacts with a number of host
cellular proteins [13,14]. NS1 functions as an IFN antago-
nist to inhibit IFN production and signaling (reviewed in
[13]). NS1 blocks the recognition of dsRNA by the cyto-
plasmic pathogen recognition receptor RIG-I (retinoic
inducible gene 1) [15] and therefore limits the activation
of IFN transcription [16,17]. NS1 also acts post- tran-
scriptionaly, to inhibit the 3’-end processing of host
mRNA including IFN mRNA by binding to CPSF30
(cleavage and polyadenylation specificity factor 30) [18]
and PABPNI (poly-A-binding protein nuclear I) [19].
NS1 also directly binds the IFN effectors PKR and 2’-5’
OAS (oligo adenylate synthetase) to counteract inhibition
of viral protein synthesis [20] and viral RNA degradation
respectively [21]. NS1 is also involved in enhancing viral
protein synthesis by interacting with the viral mRNA
[22], the translation initiation factors eIF4GI (eukaryotic
initiation factor 4GI) [23], and PABPI (poly-A-binding
protein 1) [24]. NS1 can also limit the early induction of
apoptosis by interacting with Pi3K and inducing Akt
phosphorylation [24,25]. Although some of these func-
tions attributed to NS1 can vary among strains, these
mechanisms (and presumably their modulation) allow
NS1 to escape the innate immune response and increase
viral replication and growth [13,26].
With respect to the role of the NS1 protein in viru-
lence, previous studies have identified single mutations in
the NS1 gene (S42P, D92E and V149A) as well as multi-
ple mutations in the PDZ ligand domain that increased
viral pathogenicity [27-30]. Furthermore studies of viru-
lence of pathogenic avian A/HK/156/97-like H5N1
showed that the NS1 gene mediated increased virulence
in the mouse model [31] and swine models [27]. In con-
trast, other studies have identified F103L and M106I
mutations in this H5N1 NS1 gene that result in a loss of
the ability to bind the cleavage and polyadenylation spe-
cificity factor and inhibit IFN induction when transferred
into A/Udorn/1/1972 (H3N2) virus [32]. Here we show
that the F103L and M106I NS1 gene mutations are adap-
tive and control IAV replication and virulence.
Materials and methods
Cells and viruses
M a d i n - D a r b yc a n i n ek i d n e y( M D C K )c e l l s ,h u m a n
embryonic kidney cells (293T), mouse kidney epithelial
cells (M1), and human lung epithelial cells (A549) were
maintained in complete minimum essential medium or
Dulbecco’s Modified Eagle Medium (Gibco, Carlsbad,
USA) supplemented with L-glutamine (2 mM), penicillin
(100 U/ml), streptomycin (100 μg/ml) and fetal bovine
serum (to 10%).
The prototype A/HK/1/68 (H3N2) (HK-wt) (obtained
from the Laboratory center for Disease Control, Health
Canada) having an LD50 of >10
7.7 pfu/ml in mice was
used to generate virulent mouse-adapted strains
[8,33,34].
Cloning of the viral NS genes in bidirectional reverse
genetics plasmids
The NS cDNA of A/HK/1/68 wt was inserted into pLLB
vector by ligation independent cloning [35] and PCR
directed mutagenesis was used to introduce point muta-
tions (F103L, M106I, and F103L + M106I) into the HK-
wt NS gene. To improve the efficiency of ligation inde-
p e n d e n tc l o n i n g ,t h ev e c t o ra n di n s e r tD N Aw e r et r e a -
ted with T4 DNA polymerase before transformation of
E. coli as described [36].
The NS genes of A/Chicken/Beijing/1/95-H9N2 (Ck/
Bj/95) (obtained from China Agricultural University)
and A/Hong Kong/156/97-H5N1 (A/HK/156/97)
(Genbank AF036360) (synthesized by Biomatic Corpora-
tion, Cambridge, Ontario) were cloned into the pHH21
and pLLB plasmids respectively by homologous recom-
bination as described [37]. The NS1 amino acids 103L
and 106I sites of both Ck/Bj/95 and A/HK/156/97 were
mutated to 103F and 106M by PCR directed mutagen-
esis. The remaining 7 gene segments of A/PR/8/34 and
A/WSN/33 were obtained from R. Webby (St. Judes
Children’s Research Hospital, Memphis) and Y. Kawaoka
(University of Madison Wisconsin) respectively.
Reverse genetics
Each of the NS plasmid constructs along with the 7
plasmids encoding the viral structural genes of A/PR/8/
34 (0.65 μg/plasmid) were mixed with lipofectamine
2000 (Invitrogen, Carlsband, USA) according to the
manufacturer’s instructions and incubated for 30 min at
RT. The plasmids and the transfection reagent were
added into a monolayer of 293T cells, 16 h post trans-
fection, the transfection mix was replaced by opti-mem
(Invitrogen, Carlsbad, USA) supplemented with TPCK
trypsin (1 μg/ml) (Thermo Fisher Scientific, Ottawa).
Forty-eight hours post-transfection the cell supernatant
was collected and inoculated in 10-day old embryonated
specific pathogen free embryonated eggs (Canadian
Food Inspection Agency, Ottawa) for virus propagation
at 37°C for 48 hours. The allantoic fluid was collected
and viral yield was assessed by plaque assay. The NS
gene sequence of the rescued viruses was verified by
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onto the A/WSN/33 backbone using the 12 plasmid sys-
tem as described [38].
Growth of the recombinant viruses in vitro
Monolayers of MDCK and A549 cells were washed
twice with 1 × PBS and infected with each of the four
rPR8 viruses at an MOI of 0.001 in presence of TPCK
trypsin (1 μg/ml) in triplicate. The supernatant was col-
lected at 12, 24, 48 and 72 hours post infection (hpi)
and viral titer was assessed by plaque assay in duplicate
for each sample.
Plaque Assay
Virus samples were serially diluted in PBS. Six well
plates of confluent monolayers of MDCK cells were
washed twice with PBS and then infected with 100 μlo f
the different virus dilutions in duplicate for each dilu-
tion. The plates were incubated at 37°C for 30 min to
allow virus adsorption. Following adsorption, the cells
were overlayed with 0.65% agarose (Invitrogen, Carlsbad,
USA), in complete MEM supplemented with TPCK
trypsin (1 ug/ml). The plates were incubated at 37°C
and 3 days post incubation plaques were fixed with
Carnoy’s fixative (three parts acetic acid to one part
methanol v/v).
Growth of the recombinant viruses in vivo
Groups of eleven BALB/c mice (4-to-6-week-old females
from Charles River Laboratories, Montreal, Quebec,
Canada) were infected intranasally under halothane
anesthesia with 5 × 10
3 pfu of each of the rPR8 viruses
i nav o l u m eo f5 0μl [34]. Mice were sacrificed at days
1, 2, 3, 5 and 7 post infection. Lungs from two mice
were collected for each of the days except for day 2
where three mice were sacrificed. Organs were weighed,
diluted 1:4 in PBS and homogenized by sonication for
quantification by plaque assay. The same protocol was
applied for the rWSN viruses. However, two mice
were collected at each of 1, 3, 5 and 7 days post infec-
tion (dpi).
Mouse Survival Assay
Groups of 5 BALB/c mice were infected intranasally
with 5 × 10
6 pfu of rPR8-HK-NS (NS-WT and variants)
and 10
6 pfu for the recombinant rWSN viruses. Groups
of 3 mice were infected intranasally with 10
4 pfu of the
rPR8-H5N1-NS viruses. Mortality was monitored for
14 dpi. Body weight was recorded daily and the LD50
was calculated by the Karber-Spearman method [39].
Ethics Statement
The animal studies were carried out in compliance with
the guidelines of the Canadian Council on Animal Care
(CCAC) as outlined in the Care and Use of Experimental
Animals, Vol.1, 2nd Edn. (1993), which are internation-
ally recognized as “best-practices” by the International
Council for Laboratory Animal Science (ICLAS). The
animal study protocol was approved by the University of
Ottawa Animal Care Committee (Protocol Number:
BMI-85). Efforts were made to minimize suffering and
mice were euthanized at humane end-points when infec-
tions resulted in greater than 25% body weight loss plus
respiratory distress.
Immunofluorescence staining of BALB/c lungs
BALB/c mice were infected intranasally with 10
5 PFU of
each of the recombinant viruses and lungs were col-
lected two dpi. Lungs were inflated and fixed with 3.7%
formaldehyde as described earlier [40]. Lung sections
were stained as described previously [8]. Rabbit anti-PR8
and anti-WSN primary antibodies that had been
pre-adsorbed with mouse lung extract were used for
immunohistochemistry. Images were taken at 20 × mag-
nification using an Olympus BX50 microscope and pro-
cessed in a parallel manner using Photoshop 7.0.
Rate of viral protein synthesis
Monolayers of MDCK were infected with the different
r P R 8v i r u s e sa tM O I=3 .T w o ,4 ,6a n d8h p i ,t h ec e l l s
were pulse-labeled with 80 μCi/ml
35Sc y s t e i n ea n d
methionine for one hour in cysteine and methionine
free media (Gibco, Carlsbad, USA). Post labeling, the
cell lysates were collected with 1 × sodium dodecyl
sulfate (SDS) sample buffer. The rate of viral protein
synthesis was then assessed by SDS page gel electrophor-
esis and autoradiography as previously described [41].
Interferon-b ELISA Assay
Monolayers of M1 cells were infected with each of the
rPR8 and rWSN viruses at an MOI of 2. Twenty-four
hours post infection the cell supernatants were collected
and tested for IFN-b production. Infection of M1 cells
with the VSV Indiana Δ 51 mutant that has a defect in
the ability to block IFN induction was performed as a
positive control using identical conditions [42]. Mouse
IFN-b was titrated relative to mouse IFN-b standards by
commercial ELISA as described by the manufacturer,
PBL Biomedical Laboratories (New Jersey, USA).
Interferon sensitivity
Monolayers of M1 cells were treated with 200 U/ml of
murine IFN-b (Sigma, St. Louis, USA) for 24 hours in
triplicate assays. Twenty-four hours post treatment, the
cells were washed twice with 1 × PBS prior to infection
w i t ht h er P R 8v i r u s e sa tM O I=1( 1 . 5×1 0
6 PFU per
35 mm dish) for 30 min at 37°C. Following infections,
the cells were washed twice with 1 × PBS, and serum
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The supernatant was then collected at 0, 8, 24 and 48
hpi and the viral titer was assessed by plaque assay (in
duplicates for each individual infection). The same
experiment was done in parallel but without prior
IFN-b treatment.
Statistical analysis
Statistical significance was measured using the student
t-test (Numbers, 09 v.2.0.4) using the parameters of
equal variance and two-tailed significance (unless other-
wise indicated) with a probability of ≤ 0.05 considered
as statistically significant. Values were calculated as
means +/- standard deviation for sample size > 2 and
+/- standard error for sample sizes of 2 (for some of the
values in Figures 1c as well as 6b).
Results
Sequence Analysis of the mouse adapted strains
In order to identify nonsynonymous NS1 gene muta-
tions that control virulence we generated virulent mouse
adapted variants of A/HK/1/68 and compared their NS1
sequence changes to those found in the virulent H5N1
variant A/HK/156/97. Sequence analysis of the NS1
genes of 42 mouse-adapted clones identified two groups
of variants MA20-B, -C and -D [33,34] as well as MA-
51, -52 and -53 [8,33] (Table 1) that possessed the
F103L and M106I mutations respectively and thus were
convergent with highly pathogenic H5N1 IAV isolated
from humans in Hong Kong in 1997 (A/Hong Kong/
156/97-like viruses) [10]. This indicated that these muta-
tions were under positive selection and were therefore
functionally important such that they may be involved
in increasing replicative fitness and virulence of the
mouse adapted variants, MA20c and MA51, with
increase in LD50 values of 10
2.5 and 10
5.5 respectively
(relative to the HK-wt parent virus, LD50 >10
7.7 pfu).
Because the F103L and M106I mutations have been
associated with increased IFN-b induction in reassor-
tants of the A/Hong Kong/156/97(H5N1) NS1 gene on
the A/Udorn/1/1972 (H3N2) backbone [32] we mea-
sured the IFN-b induction by the parental HK-wt and
the MA20c (F103L) and MA51 (M106I) mutant viruses
in mouse M1 cells. Using an MOI of 2, the MA20c and
MA51 viruses induced low levels of IFN-b after 24 h of
incubation that were not significantly different from
HK-wt (12 +/- 8 pg/ml).
Growth of rPR8 NS1 mutant viruses in vitro
To test the role of F103L and M106I mutations on
growth, we first generated viruses possessing the HK-wt
(106F + 106M), or F103L, M106I and F103L + M106I
mutations on the A/PR/8/34 backbone. To compare the
growth kinetics of viruses that differed due to specific
change in their NS1 genes, rPR8-HK-NS-wt, rPR8-HK-
NS F103L, rPR8-HK-NS-M106I, and rPR8-HK-NS-
F103L + M106I were used to infect MDCK and A549
epithelial cells, in triplicate, at a low MOI (0.001) to
initiate multicycle replication. Supernatants were col-
lected at 12, 24, 48 and 72 hpi and were assayed for
yield of infectious progeny virus as measured by plaque
assay. All the mutants had a significantly increased
ability to grow in MDCK cells compared to rPR8-HK-
NS-wt with the rPR8-HK-NS-M106I and rPR8-HK-NS-
F103L + M106I mutants growing to higher titers than
the rPR8-HK-NS-F103L mutant (Figure 1a). Growth was
particularly enhanced at early times (12 and 24 hpi) (P
< 0.05) in the three mutant viruses compared to rPR8-
HK-NS-wt, where the F103L mutation enhanced yields
by 6 and 2 fold respectively; relative to the M106I con-
taining, single and double, mutants that showed 20
and 9, as well as 7 and 5 fold enhanced yields for these
respective viruses at 12 and 24 hpi. However, at the 48
hpi time point, only rPR8-HK-NS-M106I, and rPR8-
HK-NS-F103L+M106I viruses grew significantly better
than rPR8-HK-NS-wt (P < 0.05) and at 72 hpi, the dou-
b l em u t a n tw a st h eo n l yv i r u st h a tg r e wt oas i g n i f i -
cantly higher titer than the rPR8-HK-NS-wt virus (P <
0.05) (Figure 1a).
In contrast, growth of the different mutants in A549
cells was comparable to rPR8-HKNS-wt at early time
points (i.e. 12 and 24 hpi), whereas at later time points
(48 and 72 hpi) there was a trend to increased yield for
the NS1 mutants where the rPR8-HK-NS-M106I and
rPR8-HK-NS-F103L + M106I mutants demonstrate sta-
tistically significant enhanced growth compared to
rPR8-HK-NS-wt at 48 hpi (P < 0.05) (Figure 1b). There-
fore, the NS1 mutations increased viral replication and
growth in vitro compared to the rPR8-HK-NS-wt in
MDCK and, in the case of rPR8-HK-NS-M106I and
rPR8-HK-NS-F103L + M106I mutants, in A549 cells
and thus demonstrate their adaptive nature in both
human and canine cells.
Growth of rPR8 mutant viruses in vivo
The three mutant rPR8 viruses along with the rPR8-HK-
N S - w tw e r eu s e dt oi n f e c tg r o u p so f1 1B A L B / cm i c e
with 5 × 10
3 pfu each via the intranasal route, and their
lung growth properties in lung tissue were compared.
rPR8-HK-NS-wt virus reached a peak titer of 3.7 × 10
4
pfu/g in mouse lungs at 2 dpi and was cleared from the
lungs by 5 dpi (Figure 1c). All the NS1 adaptive muta-
tions significantly increased replication in mouse lung
compared to rPR8-HK-NS-wt at 1 dpi (P < 0.05) and
for each of the single mutants 2 days after infection (P <
0.01). Thereafter, viral growth was increasingly enhanced
(100 fold at 3 dpi (P < 0.05), and 5 logs by 5 dpi (P <
0.01)) (Figure 1c). Thus all the NS1 mutants delayed
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rPR8-HK-NS-wt. In addition, rPR8-HK-NS-F103L and
the double mutant rPR8-HK-NS-F103L + M106I
demonstrated enhanced viral growth relative to the
rPR8-HK-NS-M106I mutant at 5 dpi (Figure 1c). This
indicated that both of the mouse adaptive mutations,
F103L and M106I, were associated with increased repli-
cation in mouse lungs such that they grew faster and to
a higher yield as well as persisted longer in the mouse
lung compared to rPR8-HK-NS-wt. The level of IFN-b
Figure 1 Increased virulence and viral growth of NS1 mutants in in vitro and in vivo systems. A. Growth of rPR8 mutant viruses in MDCK
cells. B. Growth of rPR8 mutant viruses in A549 human epithelial cells. Monolayers of MDCK or A549 cells were infected with each of the
recombinant viruses at MOI = 0.001 in presence of trypsin. Supernatants were collected at 12, 24, 48 and 72 hpi and viral titer was assessed by
plaque assay. Values are shown as averages +/- standard deviation. C. Growth of rPR8 mutant viruses in BALB/c lungs. Groups of 11 BALB/c mice
were infected intranasally with 5 × 10
3 PFU. Lungs were collected at days 1, 2, 3, 5 and 7 post infection. Organs were sonicated on ice and viral
titer was assessed by plaque assay. Values are shown as averages +/- standard deviation at day 3 pi and +/- standard error for the rest of the
time points. D. Virulence of rPR8 mutant viruses in BALB/c. Groups of 5 BALB/c were infected intranasally with 5 × 10
6 pfu with the rPR8 viruses.
Survival was monitored for 14 dpi.
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extracts. No virus was detected in the liver of any of the
mice indicating that the viruses are incapable of growing
systemically in BALB/c mice following infection at 5 ×
10
3 pfu (data not shown).
Virulence of the rPR8 mutant viruses in BALB/c mice
To compare the virulence of the different recombinant
viruses, groups of 5 BALB/c mice were infected intrana-
sally with 5 × 10
6 pfu of the different recombinants and
mortality was monitored for 14 days pi. Although the
LD50 of the rPR8 virus was 10
3.5 pfu (data not shown),
introduction of the HK-wt NS1 gene onto this backbone
resulted in rPR8-HK-NS-wt that was avirulent in mice
and did not result in mortality (LD50>10
7 pfu) indicating
an important role for PR8 NS1 in virulence (Figure 1d).
Similar infection of mice with 5 × 10
6 p f uo fe a c ho ft h e
three mutants resulted in mortality within each group
(Figure 1d). A single mutation (F103L) introduced to the
HK-wt NS gene resulted in 40% mortality in BALB/c,
while the infection with the viruses possessing M106I
and F103L + M106I mutations resulted in a 20% mortal-
ity rate by 4 and 7 dpi respectively. Consistent with their
increased growth in mouse lungs, the NS1 adaptive
mutations increased virulence in vivo as observed by
mortality when compared to the rPR8-HK-NS-wt.
103L and 106I increase tropism in BALB/c lungs
The recombinant PR8 viruses were used to assess the
extent of infection and tropism in BALB/c mouse lungs
infected with 10
5 pfu at 2 dpi by immunofluorescent stain-
ing. The lungs infected with the rPR8-HK-NS-wt showed
a minimal pattern of detectable infection with scattered
alveolar staining and no bronchiolar tissue infections (Fig-
ure 2b). The NS1 mutants showed an increased extent of
alveolar tissue infection with larger foci in the lungs that
was more pronounced in the single mutants rPR8-HK-
NS-F103L and rPR8-HK-NS-M106I compared to rPR8-
HK-NS-wt (Figure 2b, c, d, e), whereas no bronchiolar
infections were observed for any of the mutants.
Rate of viral protein synthesis
The mouse adapted NS1 mutations 103L and 106I map
to binding sites for cellular translational (eIF4G-I and
PABPI) and post-transcriptional factors (CPSF-30). To
explore whether the enhanced growth and pathogenicity
of the mutant viruses correlated with enhanced viral
Table 1 NS1 mutations in MA variant clones of A/HK/1/68
(HK-wt) H3N2
Virus NS1 Amino Acid positions
2 23 98 103 106 124 125 180 226 227
HK-wt D V L F M M D V V R
HKMA20 (MA20) - A - - - -----
HKMA20a (MA20A) - A - - - -----
HKMA20b (MA20B) - - - L - -----
HKMA20c (MA20C) - - - L - -----
HKMA20d (MA20d) - - - L - -----
HK4MA21-1 (MA41) - - - - V -----
HK4MA21-2 (MA42) - - - - V -----
HK4MA21-3 (MA43) - - - - V I ----
HK5MA21-1 (MA51) - - - - I -----
HK5MA21-2 (MA52) - - S - I -----
HK5MA21-3 (MA53) - - S - I -----
HK6MA21-2 (MA62) - - - - - - - A - -
HK6MA21-3 (MA63) - - - - - - - A - -
HK9MA21-3 (MA93) N - - - - -----
HK10MA21-2
(MA102)
- - - ---G---
HK10MA21-3
(MA103)
- - - -----I-
HK11MA21-1
(MA111)
- - - ---G---
HK11MA21-2
(MA112)
- - - ------K
Figure 2 103L, 106I and 103L+106I mutations enhance viral
tropism in BALB/c lungs. BALB/c mice were infected intransally
with 10
5 pfu and lungs were collected 2 dpi. The lungs were
inflated and fixed with 3.7% formaldehyde and lung sections were
stained with anti-PR8 antibody. The bronchiolar regions are
indicated by an arrow. A. Mock uninfected lungs B. rPR8-HK-NS-WT
infected lungs C. rPR8-HK-NS-F103L infected lungs D. rPR8-HK-NS-
M106I infected lungs E. rPR8-HK-NS-F103L + M106I infected lungs.
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determined by
35S-met + cys labeling of infected MDCK
cells. MDCK cells were infected with the different rPR8
viruses at MOI = 3 and cells were pulse-labeled with
35S
met and
35S cys for 1 h at 2, 4, 6 and 8 hpi before SDS
page and autoradiography. A representative gel for 1 of
2 independent experiments that demonstrated the same
patterns is shown in Figure 3. The rate of viral protein
synthesis was enhanced by the F103L mutation at all
time points as demonstrated for the M1 and NS1 bands
with the most dramatic increase shown early after infec-
tion (at 2 hpi). M106I also enhanced viral protein synth-
esis at 2 hpi but not at later time points (Figure 3). The
double mutant produced similar or reduced levels of
protein synthesis compared to rPR8-HK-NS-wt at all
times (Figure 3). These data indicated that each of the
F103L and M106I mutations resulted in more rapid
gene expression seen at the level of protein synthesis,
but that these mutations in combination were not as
effective at enhancing protein synthesis.
NS1 mouse adaptive mutations increase replication in
untreated mouse cells and following IFN-b treatment
NS1 is involved in IFN antagonism as the NS1 deleted
IAV A/PR/8/34 mutants is only capable of replicating in
IFN unresponsive cells or mice such as Vero cells or in
STAT-1 knock-out mice [43]. Therefore, to determine
whether the difference in virulence and replication
between the mutant viruses and the rPR8-HK-NS-wt was
due to NS1 IFN antagonistic effect, the viral growth in
mouse M1 cells was assessed in the presence and absence
of IFN-b pre-treatment. Monolayers of M1 cells were
either untreated or pre-treated with 200 U/ml of murine
IFN-b for 24 hours. Twenty-four hours post treatment,
cells were washed with PBS and infected in triplicate with
the different rPR8 viruses at MOI = 1 in the presence of
TPCK trypsin (1 μg/ml) and the cell supernatants were
collected at 0, 8, 24 and 48 hpi. Without prior IFN-b treat-
ment, the rPR8-HK-NS-wt reaches a peak of 3.8 × 10
4
pfu/ml at 24 hpi that was comparable to each of the single
mutants at that time, while each of the mutations (103L
and 106I) enhanced growth at the earliest (8 hpi) (by > 6
fold and >4 fold for the F103L and M106I mutants respec-
tively) and at the latest time point (48 hpi) compared to
rPR8-HK-NS-wt (P < 0.01) (Figure 4a). The double
mutant grew better than the rPR8-HK-NS-wt at 8 hpi but
to lower yields compared to each of the single mutants,
and was reduced to lower than the rPR8-HK-NS-wt levels
thereafter. Following IFN-b pretreatment, the rPR8-HK-
NS-wt reached a peak of 3 × 10
3 pfu/ml at 8 hpi and all
the viral mutants grew better than the rPR8-HK-NS-wt at
this time (P < 0.01 for the single mutants and P < 0.05 for
the double mutant) (>7 fold increase by F103L mutant).
At later time points (24 and 48 hpi) only the single
mutants 103L and 106I were able to enhance growth in
the presence of IFN-b relative to rPR8-HK-NS-wt (P ≤
0.01) (Figure 4b). Thus, following IFN-b treatment, the
rPR8-HK-NS-F103L and rPR8-HK-NS-M106I mutants
had demonstrated enhanced growth throughout infection
relative to rPR8-HK-NS-wt, but enhanced growth was
only seen at early times for the double mutant.
103L and 106I in H5N1 NS1 control virulence in
BALB/c mice
To further assess the virulence associated with 103L and
106I sites, the H5N1 NS, that possess the L and I amino
acids in the 103 and 106 sites respectively, was rescued
onto a A/PR/8/34 backbone. The virulence of this virus
was determined in BALB/c mice following intranasal
infection with 10
4 pfu. The rPR8-H5N1-NS-103L+106I
resulted in 100% mortality by 8 dpi indicating a LD50 of
<10
3.5 (Figure 5a) that was associated with 26% body
weight loss at the time of death (Figure 5b). We then
mutated the 103L and 106L sites back to consensus and
generated a PR8 recombinant possessing the H5N1-NS-
L103F + I106M. The rPR8-H5N1-NS-L103F + I106M
did not cause any mortality in mice, LD50 of >10
4.5 (Fig-
ure 5a); in addition, the infected mice only lost 4% of
their body weight (Figure 5b). Therefore, the 103L and
106I are associated with severe disease and >10 fold
increased virulence in the H5N1 NS1 gene.
103L and 106I in H9N2 NS1 control virulence in
BALB/c mice
The properties of 103L and 106I mutations were also
studied in the context of the Ck/Bj/95 (H9N2) NS gene,
that possesses both 103L and 106I residues, on another
mouse adapted backbone A/WSN/33 backbone. We
tested this backbone because WSN NS1 inhibits IFN-b
Figure 3 Effect of F103L, M106I, and F103L + M106I NS1
mutations on the rate of viral protein synthesis in MDCK.
MDCK cells were infected with each of the rPR8 viruses at a MOI =
3 and pulsed for 1 hour with
35S at 2, 4, 6, and 8 hpi. Cell lysate
was collected after pulse and used for SDS page and
autoradiography. The experiment was performed twice and a
representative SDS-page analysis is shown.
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30 binding in contrast to PR8 NS1 that does not bind
CPSF-30 [44] (reviewed in [13]) and recent findings that
multiple polymerase components act to block IFN
induction [45,46] suggests that IFN antagonism is a
function of multiple genes that may differ among
strains. We then mutated the Ck/Bj/95 (H9N2) NS gene
to possess L103F + I106M to generate the consensus
sequence at these sites. The virulence and growth of the
recombinant WSN virus having the unmodified H9N2-
NS1 gene possessing 103L and 106I mutations was
determined in BALB/c mice. The virus was highly viru-
lent in BALB/c mice causing 100% mortality 5 dpi fol-
lowing intranasal infection with 10
6 pfu (Figure 6a).
When both sites were mutated to L103F + I106M, the
virus lost its ability to cause fatal infection at this dose
in the mouse, as the virus did not cause any mortality
throughout 14 dpi, thus the LD50 was reduced by >10
fold (Figure 6a).
The ability of the two rWSN viruses (rWSN-Ck/Bj-
NS-103L + 106I and rWSN-Ck/Bj-NS-L103F + I106M)
to grow in BALB/c mice was also determined by infect-
ing groups of 8 mice intranasally at a lower infection
dose of 5 × 10
3 p f u .T h ep r e s e n c eo ft h eH 9 N 2N S 1
103L + 106I residues increased growth in BALB/c lungs
by 100 fold at 1 dpi and >10 fold at 3 and 5 dpi relative
to the L103F + I106M mutant that was significantly dif-
ferent by paired t-test (P ≤ 0.01) (Figure 6b). The
growth was also more persistent at 7 dpi with >2 logs
increased lung titer due to the presence of F103L +
M106I mutations (P < 0.05) (Figure 6b). Thus the Ck/
Bj/95 NS1 F103L + M106I mutations conferred both
increased replication and virulence in mouse lungs.
We also assessed the extent of lung infection using
immunofluorescent staining of infected lung sections to
show that the presence of L103F and I106M mutations
in the Ck/Bj/95 H9N2-NS1 gene on the WSN backbone
resulted in lung infection that was restricted to specific
foci in the bronchiolar epithelium (Figure 6c). In con-
trast, the presence of 103L and 106I in the H9N2-NS1
Figure 4 Interferon sensitivity of the rPR8 viruses in mouse
epithelial cell lines. A. Growth curve of the rPR8 mutant viruses in
M1 cells. Monolayers of M1 cells were infected with each of the
rPR8 viruses at MOI = 1. Cell supernatants were collected at 0, 8, 24
and 48 hpi. Viral titer was assessed by plaque assay. B. Growth curve
of the rPR8 mutant viruses in M1 cells in the presence of IFN-b.
Monolayers of M1 cells were treated with 200U/ml of murine IFN-b.
Twenty-four hours post treatment; monolayers were infected with
each of the rPR8 viruses at MOI 1. Cell supernatants were collected
at 0, 8, 24 and 48 hpi. Viral titer was assessed by plaque assay.
Values are shown as average +/- standard deviation.
Figure 5 Virulence and body weight loss are increased by 103L
and 106I NS1 mutations in rPR8- H5N1-NS. A. Groups of 3 BALB/
c mice were infected intranasally with 10
4 pfu with the different
rPR8 viruses. Survival was monitored for 9 dpi. B. The percent of
body weight loss was calculated relative to body weights that were
recorded daily throughout the whole course of the experiment.
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bronchiolar and alveolar tissues to encompass all of the
alveoli except for regions around the bronchioles (Figure
6d). The extent of lung infection correlated with viral
replication and virulence for both viruses in BALB/c
mice. Thus we have identified two mutations in the NS1
gene that mediated increased replicative fitness and viral
tropism in the mouse lung. Therefore the presence of
Leu at position 103 and an Ile at position 106 are neces-
sary and sufficient for a virus with a human (A/HK/1/
68) on the A/PR/8/34 backbone or the avian (A/HK/
156/97 and Ck/Bj/95) NS genes on either the A/PR/8/
34 or A/WSN/1933 backbones respectively, to become
virulent and enhance growth in BALB/c mice.
Interferon induction by NS1 mutants in M1 cells
As both the F103L and M106I mutations were asso-
ciated with greater levels of growth than the double
mutant at later times following IFN-b pretreatment, we
assessed the amount of IFN-b production during infec-
tion, which could explain the differences in mutant gene
functions among these mutants. To assess the roles of
our NS mutants in controlling IFN-b production, mono-
layers of M1 cells were infected with each of the rPR8
viruses at MOI = 2. Twenty-four hours post infection,
cell supernatants were collected and IFN-b production
was assessed by ELISA. Infection with the HK-wt and
the PR8-wt viruses resulted in low or undetectable levels
of IFN-b respectively indicating that both NS1 (and pos-
sible roles of the NEP) proteins can suppress IFN-b
induction on their respective genetic backbones. The
rPR8-HK-NS-wt recombinant also induced low levels of
IFN-b (22 pg/ml) whereas each of the recombinants
rPR8-HK-NS-F103L or rPR8-HK-NS-M106I induced 2
and 3 fold more IFN-b respectively compared to rPR8-
HK-NS-wt (40 and 68 pg/ml respectively) while the
double mutations together had a cumulative effect on
increasing IFN-b induction to 113 pg/ml (P < 0.001)
(Figure 7). The increased IFN-b induction levels pro-
duced by the different mutants is consistent with the
reduced viral growth at later times in M1 cells relative
to rPR8-HK-NS-wt, when increasing amounts of IFN-b
Figure 7 Interferon production in M1 cells. Monloayers of M1
cells were infected with the parental recombinant viruses rHK-wt,
rPR8-wt and rWSN-wt and the different recombinant viruses, rPR8-
HK-NS, rPR8-H5N1-NS and rWSN-Ck/Bj-NS viruses at MOI = 2.
Twenty-four hours post infection, the supernatants were collected
and the level of IFN-b production was assessed by ELISA. The IFN-b
levels were compared to a positive control (VSV Δ51 infection).
Values are shown as average +/- standard deviation.
Figure 6 Growth, virulence and viral tropism are increased by
103L and 106I NS1 mutations in rWSN-Ck/Bj-NS. A. Groups of 5
BALB/c mice were infected intranasally with 10
6 pfu with the
different rWSN viruses. Survival was monitored for 14 dpi. B. Groups
of 5 BALB/c were infected intranasally with 5 × 10
3 pfu with the
rWSN viruses. Lungs were collected at days 1, 3, 5 and 7 pi,
sonicated and the viral titer was assessed by plaque assay. Values
are shown as average of 2 replicates +/- standard error for each
value. C. BALB/c mice were infected intransally with 10
5 pfu of
rWSN-Ck/Bj-NS-L103F + I106M and lungs were collected 2 dpi. The
lungs were inflated and fixed with 3.7% formaldehyde and lung
sections were stained with anti-WSN antibody. The bronchiolar
regions are indicated by an arrow. D. rWSN-Ck/Bj-NS-103L + 106I
infected lungs. Statistical analysis was performed using the
parameters of paired and two-tailed student’s t-test with probability
≤ 0.01.
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by the effect of IFN-b pretreatment in Figure 4b). The
extent of viral growth was thus inversely correlated with
IFN-b induction where the rPR8-HK-NS-F103L virus
grew to the highest yield in M1 cells in the presence
and absence of IFN-b and induced the least amount of
IFN-b, while the double mutant grew the least with and
without IFN-b pre-treatment and induced the highest
levels of IFN-b compared to the rest of the mutants.
The increased IFN-b induction by the double mutant
explains the reduced replication of this virus relative to
the single mutants.
The levels of IFN-b induction in M1 cells following
infection with the recombinants that possess the H5N1
NS and Ck/Bj/95 NS genes were also measured and
showed minimal levels of IFN-b induction at 24 hpi.
Interestingly, mutating the NS1 sites 103L and 106I to
L103F and I106M in either of these NS1 genes resulted
in viruses of low and comparable interferon induction
indicating a role of other NS1 gene mutations in the
regulation of IFN-b induction by these viruses. The
effectiveness of the influenza NS1 mutants to inhibit
IFN-b i n d u c t i o nw a ss h o w ni nc o m p a r i s o nw i t ht h e
VSV Δ 51mtuant that has a defect in its ability to block
innate immunity and resulted in 1,306 pg/ml IFN-b.W e
can conclude that IFN-b induction is controlled by mul-
t i p l eg e n e t i cf a c t o r si n v o l v i n gt h en a t u r eo ft h eN S 1
gene as well as interactions with the genetic backbone.
Discussion
Here we demonstrated that both the IAV NS1 F103L
and M106I mutations were adaptive mutations that
increased replicative abilities in cells of multiple species
as well as virulence in the mouse lung. The observation
that both the NS1 F103L and M106I mutations were
under positive selection and were therefore adaptive
mutations was evident by their increased prevalence in
mouse adapted populations; where they were found in 3
of 6 [34] and 3 of 3 virus clones in independent mouse-
adapted populations (Table 1). This indicated that these
mutations conferred a selective advantage relative to the
wild type NS1 genes possessing 103F and 106M.
Although we observed a loss of ability to inhibit IFN-b
induction on the PR8 backbone, this property was
separable from an enhanced ability for protein synthesis
and viral replication. Therefore, there appeared to be a
counterbalance between the inhibitory effects of IFN-b
induction and enhanced overall function seen at the
level of replication and virulence for both of these muta-
tions. In our experiments, the F103L and M106I muta-
tions enhanced IFN-b induction only when transferred
onto the foreign, A/PR/8/34, genetic background. This
was also reported for the A/HK/156/97(H5N1) NS1
gene that also possessed these mutations and did not
induce IFN-b on its native backbone but did when
transferred onto the A/Udorn/1/72 (H3N2) backbone
[32]; that was correlated with the loss of CPSF-30 bind-
ing and thus inhibition of host gene expression. The dif-
ferent abilities to inhibit IFN-b induction among viruses,
that possessed the same combinations of mutations,
103L and 106I versus 103F and 106M, but that differed
in their NS1 genes (A/HK/1/68, A/HK/156/97 (H5N1)
or Ck/Bj/95 (H9N2)) as well as virus backbones (PR/8/
34 and WSN/33), indicates that inhibition of IFN-b
induction is not only controlled by the NS1 gene but
also by epistatic interactions with the other virus gene
products. It has been reported that the A/HK/156/97
( H 5 N 1 )w a sa b l et os u p p r e s sI F N - b i n d u c t i o ni nt h e
context of its NS1 gene, possessing F103L and M106I
mutations, due to properties of its NP and PA genes
[47]. This is consistent with the recently described roles
for PA, PB1 and PB2 genes in blocking IFN induction
by binding to the mitochondrial antiviral signaling pro-
tein (MAVS) [45,46] but suggest that a functional inter-
action with NS1 protein is also involved in these (or
other undefined) processes which are downstream from
the RIG-I signal that is inhibited by NS1 [48]. Thus the
F103L and M106I mutations were not associated with
increased IFN-b induction either in A/HK/156/97
(H5N1) virus [47] or for the MA20c and MA51 mouse-
adapted viruses in which these mutations were selected,
indicating that these mutations were selected in a
genetic context that maintains suppression of IFN-b
induction. Increased IFN-b induction was also sup-
pressed for the H9N2 NS gene on the WSN backbone,
and the H5N1 NS gene on the PR8 backbone where it
was demonstrated that in the absence of increased IFN-
b induction the F103L and M106I mutations mediated a
large increase in extent of lung infection and virulence.
We have therefore demonstrated that both F103L and
M106I mutations were multifunctional, including loss of
ability to suppress IFN-b in some contexts but also
including gain-of-function that increased replicative abil-
ities and virulence. Multifunctional adaptive mutations
have been previously seen in the HA gene for individual
adaptive mutations that affect both pH of fusion and
receptor binding [8] suggesting that strongly adaptive
mutations affect more than one function.
Mechanisms of action of NS1 103L and 106I mutations
The NS1 mouse adaptive mutations demonstrated an
increased ability to antagonize IFN-b activity observed
by the enhanced ability to grow in mouse epithelial cells
following IFN-b pre-treatment when compared to rPR8-
HK-NS-wt. Increased growth of these mutants was also
greater at early times in MDCK and mouse M1 cells
consistent with greater replication at early times before
IFN-b had been induced in the infected cell cultures.
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inhibition of IFN and other host gene expression [18],
A/PR/8/34 (H1N1) viruses have been shown to have
lost CPSF binding due to mutations at positions 103
and 106 (S + I) and yet maintains the ability to block
IFN induction by preventing pre-transcriptional activa-
tion of IRF-3, NFB and c-Jun/ATF-2 as reviewed [13].
Given that the 103 and 106 amino acids also map to
regions of interaction between NS1 and cellular transla-
tional initiation factors eIF4GI and PABPI, leads to the
hypothesis of increased NS1-mediated initiation com-
plex formation on IAV mRNA for enhanced viral gene
expression due to mutations F103L and M106I. It is
also possible that these mutations affect other functions
of NS1 that are mediated by interaction with other viral
or host proteins. Several studies have identified multiple
host factors that interact with NS1 protein [13], includ-
ing the recent identification of nine PR8 viral proteins
and 20 host proteins that bind NS1 protein, all of which
may be modified in their interaction due to adaptive
mutations [14]. Future studies are needed to assess the
role of the adaptive HK-NS1 mutations on interactions
with other viral factors.
F103L and M106I Mutations enhance protein synthesis
The increased protein synthesis of the F103L NS1
mutant was clearly seen for the M1 and NS1 proteins at
all times in MDCK cells whereas the M106I mutation
increased protein synthesis at 2 hpi but not at later
times, and where the double mutant was not signifi-
cantly enhanced relative to rPR8-HK-NS-wt (Figure 3).
This may have been due to the increased induction of
IFN-b as seen for mouse cells infected with these
mutants. Thus there was an enhancement of protein
synthesis due to each mutation alone but that this was
being suppressed by the increased amounts of IFN-b
that were simultaneously expressed for F103L and
M106I in combination, thus indicating the critical role
of NS1 in inhibition of IFN-b induction.
The F103L and M106I mutations increased virulence of
human and avian NS1 genes
Both HK-NS1 F103L and M106I mutations enhanced
the level and duration of replication resulting in
increased virulence in the mouse lung where viral titers
were 10
4 to 10
5 fold higher at 5 dpi in infected lungs, in
contrast to rPR8-HK-NS-wt, which had viral titers
below the level of detection. Immunofluorescent staining
showed that each mutation in the HK-NS1 gene
enhanced the ability to infect clusters of cells in the
alveoli of infected mice. The extent of infection as mon-
itored by virus yield suggested that more cells were
infected in the lung for all the mutant viruses but that
both mutations in combination were not more effective
in the PR8 backbone than the F103L mutation alone,
presumably because of the increased amount of induced
IFN-b by this mutant. We also demonstrated that these
mutations were critical for the enhanced virulence of
the HK/156/97 and Ck/Bj/95 NS1 genes such that rever-
sion to L103F and I106M resulted in an IAV that was
very restricted in its ability to infect lung tissues. These
mutations were not associated with increased IFN-b
induction in M1 cells when present on the Ck/Bj/95
NS1 gene on the WSN background, or on the A/HK/
156/97 NS gene on the A/PR/8/34 backbone indicating
that the ability to block IFN-b induction was maintained
by these avian NS genes on the WSN or PR8 back-
grounds. The NS1 F103L and M106I mutations
mediated a large expansion of cell tropism for rWSN-
Ck/Bj-NS-103L + 106I where the virus infected a much
larger proportion of the lung. This effect is consistent
with a greater ability to resist inhibition by IFN-b and
paralleled the large effect of the PR8 NS1 gene on
expanding tissue tropism that was observable in PR8
infected STAT1 knockout mice when compared to virus
that had the NS1 gene deleted in the PR8 NS1 null
mutant [43].
Conclusion
In summary, we have identified two multifunctional
mutations in the NS1 gene that control virulence. The
presence of a Leu at position 103 and Ile at position 106
were selected in mice and independently in avian IAV
lineages and are required for an increase in virulence
and growth in both human A/HK/1/68 and avian (Ck/
Bj/1/95 and A/HK/156/97) NS genes as shown on mul-
tiple genetic backgrounds (A/WSN/1/33 as well as A/
PR/8/34). Therefore, we conclude that the NS1 protein
of IAV is a virulence determinant that in addition to
controlling IFN-b induction mediates gain-of-function
effects on both protein synthesis and viral replication
due to the presence of 103L and 106I that increase the
extent of lung tropism and infection.
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